Pega-One

Pega-One is a private, pre-revenue biotech focused on advancing next-generation antibody therapeutics for oncology. Its lead asset, Imgatuzumab, is a glycoengineered anti-EGFR monoclonal antibody designed to enhance Antibody-Dependent Cellular Cytotoxicity (ADCC) and Phagocytosis (ADCP), potentially improving efficacy over first-generation EGFR inhibitors. The company's strategy involves licensing and developing differentiated biologic candidates to address unmet needs in cancer care. As a relatively young company, its near-term value creation hinges on the clinical progress of its single, in-licensed asset.

Development of monoclonal antibodies utilizing Glycart glycoengineering technology to enhance Fc-mediated effector functions (ADCC and ADCP).

The anti-EGFR space is crowded with established antibodies and TKIs, and new modalities like ADCs are entering the field. Imgatuzumab must demonstrate clear clinical superiority to gain market share. It also competes with other immune-enhancing antibody platforms (e.g., Fc engineering, bispecifics) across oncology.